Autoimmune Diseases

Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.

Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.

Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.

Autoimmunity and certain autoimmune diseases have been increasing in prevalence in the United States.

Officials with the FDA have granted approval to ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.

Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.

Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.

Pharmacists can play an integral role in managing patients with inflammatory bowel disease (IBD) through medication management. 

Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.

Evidence-based recommendations focus on immunomodulators, biologics, and small molecules for the management of ulcerative colitis.

Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications. 

Osteoarthritis is the most common type of arthritis, affecting nearly 54 million people.

Biosimilar to Remicade

Delayed-release oral capsules for various forms of the disease.

Fourth indication expansion for the 2009 drug.

How to help manage two of the most common autoimmune diseases.

A new law gives pharmacists increased authority.

Currently only approved for men and transgender women; future trials expected.

Psoriasis, MS, Lupus, and RA.

Monoclonal antibody for autoimmune and neurodegenerative disorders.

Monoclonal antibody shows potential for lupus nephritis treatment.

Current phase 3 studies investigative novel, preventative approaches.

Black box warns of increased risk of blood clots and death.

TNF blocker biosimilar to Humira (adalimumab, Abbvie).